Market Closed -
Nasdaq
01:30:00 16/05/2024 am IST
5-day change
1st Jan Change
5.53
USD
-4.33%
-22.66%
+66.57%
This article is reserved for members
Not a member ?
Free registration
HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating
07/05
MT
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
07/05
CI
Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating
27/03
MT
HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating
25/03
MT
Transcript : Rani Therapeutics Holdings, Inc., Q4 2023 Earnings Call, Mar 20, 2024
21/03
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
21/03
CI
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
21/03
CI
Transcript : Rani Therapeutics Holdings, Inc. - Special Call
05/02
Rani Therapeutics Holdings, Inc. Announces Positive Topline Results from Phase 1 Study of Oral Anti-Interleukin 12/23 Antibody (RT-111)
05/02
CI
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Regarding A Imimolecular Triagonist Molecule Delivered Via Endoscope
14/12
CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
02/12
MT
Sector Update: Health Care
02/12
MT
Rani Therapeutics Stock Climbs After Share Purchase by CEO
02/12
MT
Wedbush Cuts Rani Therapeutics Holdings' PT to $8 From $20, Keeps Outperform Rating
10/11
MT
HC Wainwright Adjusts Price Target on Rani Therapeutics to $16 From $20, Maintains Buy Rating
09/11
MT
Rani Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
09/11
CI
Rani Therapeutics Holdings, Inc. Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform
02/11
CI
Rani Therapeutics Holdings, Inc. Announces Preclinical Data Supporting the Safety and Tolerability of the RaniPill® Drug Delivery Platform Following 60-Day Repeat Administration
25/23/25
CI
Rani Therapeutics Reports 'Successful' Oral Delivery of Humira in High-Capacity Pill in Preclinical Study
20/23/20
MT
Rani Therapeutics Holdings, Inc. Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
20/23/20
CI
Sector Update: Health Care Stocks Mixed Premarket Monday
18/23/18
MT
Rani Therapeutics Starts Early Stage Trial of Autoimmune Disease Treatment Candidate
18/23/18
MT
Rani Therapeutics Holdings, Inc. Initiates Phase 1 Study of Rt-111 (Ranipill® Containing Ustekinumab Biosimilar, Ct-P43)
18/23/18
CI
Rani Therapeutics Holdings, Inc.(NasdaqGM:RANI) dropped from S&P Global BMI Index
18/23/18
CI
Rani Therapeutics Holdings, Inc. Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
08/23/08
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.
More about the company
Last Close Price
5.53
USD
Average target price
11
USD
Spread / Average Target
+98.92%
Consensus
1st Jan change
Capi.
+66.57% 145M +7.52% 113B +11.38% 106B +0.52% 22.27B -12.64% 22.22B -4.04% 19.43B -37.85% 17.87B -8.58% 17.24B +7.77% 14.29B +37.41% 12.52B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**